Poultry Anticoccodial Drugs Market

Poultry Anticoccodial Drugs Market Analysis

The Poultry Anticoccodial Drugs Market size is estimated at USD 1.43 billion in 2025, and is expected to reach USD 1.74 billion by 2030, at a CAGR of 3.95% during the forecast period (2025-2030).

A significant burden of coccidiosis in poultry animals across the globe is expected to boost the market. Coccidiosis is one of the most severe enteric problems in the poultry industry. The most catastrophic Eimeria tenella outbreaks occurred in the early stages of intensive chicken farming. Coccidiosis is a widespread disease in poultry farming, leading to significant economic losses. For instance, according to a research article published in Frontiers in March 2024, avian coccidiosis can cause substantial financial losses, with an estimated global cost to the poultry industry of approximately USD 12.00 billion annually.

The high prevalence of coccidiosis drives the demand for anticoccidial drugs to control and prevent outbreaks. According to a study article published in Veterinary Medicine and Science in July 2024, a meta-analysis revealed that eimeria tenella is the most prevalent species to cause infection in chickens. Moreover, the study also recommended that addressing eimeria impact is crucial not only for safeguarding poultry health but also for sustaining the economic viability of the poultry industry. Furthermore, a research study published in the Journal of BMC Veterinary Research in May 2024 showed that the prevalence of coccidiosis disease in broiler farms in the Guangdong province of China is 98.88% at the farm level and 87.06% at the flock level.

Additionally, according to data published by veterinaria digital, in September 2022, stated that the prevalence of coccidiosis in broilers to fluctuate between 5% and 70% depending on many factors, such as high temperature, humidity conditions in India.

Thus, the burden of coccidiosis among the poultry and high prevalence of coccidiosis demands the availability of the anticoccidial drugs. As a result, market growth is expected during the analysis period.

Poultry Anticoccodial Drugs Market Trends

Ionophore Segment is Expected to Dominate the Poultry Anticoccodial Drugs Market during the Forecast Period

Ionophores are commonly used as parasiticides to prevent animal coccidiosis, including in poultry. Ionophores are commonly used in poultry farming for controlling coccidiosis, a prevalent parasitic disease among poultry. As the poultry population grows, the need for effective disease prevention and management strategies, including the use of ionophores, increases. According to the European Union Register of Feed Additives, monensin, salinomycin, lasalocid, semduramicin, and narasin are registered as coccidiostats in poultry. All of them may be used in chickens. In turkeys, only monensin, lasalocid, and maduramicin are utilized. Furthermore, lasalocid is used for the treatment and prophylaxis of pheasants, guinea fowl, quails, and partridges.

Ionophores are an effective tool to control coccidiosis. For instance, a study published in September 2024, in the Animals Journal, which revealed that coccidiostats were effective in treatment of coccidiosis and mitigation of the damage caused by the parasite, enabling desirable broiler performance. Moreover, the study also stated that narasin should be considered as a superior coccidiostat in comparison with salinomycin. The study's results can facilitate the wider adoption of coccidiostats, including ionophores, in the poultry industry, potentially leading to market growth and expansion within the ionophore segment as more producers seek these effective solutions for coccidiosis management.

Morover, in line with the supporty research study, many companies also collaborate or launch drugs boosting the segment growth. For instance, in August 2024, Huvepharma, received United States Food and Drug Administration approval of COXIDIN 90 (monensin) Type C medicated feeds. The drug is approved as an aid in the prevention of coccidiosis in broiler chickens, laying hen replacement chickens, and layer breeder replacement chickens.

Thus, favourable research studies that facilitate the wider adoption of coccidiostats like narasin and launch of product by the key players are likey to boost the segment growth.

North America Region is Expected to Dominate the Poultry Anticoccodial Drugs Market during the Forecast Period

North America is expected to dominate the poultry anticoccodial drugs market. Coccidiosis is a common parasitic disease that affects poultry, leading to significant economic losses due to reduced productivity and increased mortality. The need for effective treatment and prevention drives demand for anticoccidial drugs in the North America region.

Rising consumer awareness about food safety and the quality of poultry products prompts farmers to adopt preventive measures, including anticoccidial drugs, to maintain healthy flocks. So, key players continuously putting efforts into developing innovative drugs to treat coccidiosis. Such, continuous innovation and development activities in the North America region for more effective medicine also support the market growth. For instance, in July 2024, ZIVO Bioscience, Inc., a United States-based biotechnology company, announced the initiation of a 42-day confirmatory study. This study aims to validate the efficacy of ZIVO’s non-antibiotic, immune-modulating product designed for the prevention and treatment of coccidiosis in broiler chickens.

Moreover, in December 2023, an updated research study by Orffa revealed that its product, Excential Sapphire Q, which contain a high concentration of triterpenoid saponins and an activated aluminosilicate, successfully reduced coccidiosis pressure and enhanced performance in broiler chickens during trials conducted in the United States.

Programs providing financial support to help animal health, encourage adoption of modern disease management practices, including the use of anticoccidial drugs. This makes these medications more accessible, especially for small and medium-sized producers also a factor that drive the region growth. For instance, In March 2024, Canada's Minister of Agriculture and Agri-Food unveiled a funding initiative, allocating up to USD 1.7 million to bolster livestock health across the nation. This investment aims to bolster their efforts in preventing and preparing for foreign animal diseases in the country. With increased funding for animal health initiatives, there may be a push towards promoting best practices in disease prevention and management. This could include recommendations for the use of effective medications like anticoccidial drugs to ensure poultry health and productivity.

Thus, the region's growth during the forecast period is expected to be propelled by favorable government support and the ongoing efforts of regional players to develop innovative drugs.

Poultry Anticoccodial Drugs Industry Overview

The poultry anticoccidial drugs market is moderately competitive in nature due to the presence of big companies operating globally. Each entity contributes to this comppetativeness through unique innovations, regional launches, partnerships with diverse organizations, and promotions across various leading platforms. Some of the key players operating in the market are Boehringer lngelheim International GmbH, Elanco, Merck & Co., Inc., Huve Pharma, and Zoetis among others.

Poultry Anticoccodial Drugs Market Leaders

Poultry Anticoccodial Drugs Market News

• January 2024: Boehringer Ingelheim has unveiled Vaxxilive Cocci 3, a poultry coccidiosis vaccine, which was formerly branded as Hatchpak Cocci III. The vaccine works to stimulate the bird’s natural immune response while minimizing tissue damage
• March 2022: Amlan International launched two new natural alternatives to antibiotics for poultry and livestock, such as Phylox Feed and NeutraPath. Phylox Feed is a natural alternative to anticoccidial drugs and vaccines that can help producers increase profitability.